Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Centocor Remicade

Executive Summary

Placebo arm of Phase III rheumatoid arthritis trial (ATTRACT) has been unblinded after investigators discovered greater efficacy for infliximab in one-year x-ray data. The two-year 428-patient trial will keep the four methotrexate/Remicade treatment arms blinded but methotrexate/placebo patients will be given the option to roll into an open-label trial (PROMPT) and use low-dose Remicade (3 mg/kg every eight weeks) in combination with methotrexate. The x-ray data will be presented at the American College of Rheumatology annual meeting in Boston on Nov. 15. Centocor also denied rumors that Lilly has made an offer to purchase the company (1"The Pink Sheet" Sept. 13, p. 5)

You may also be interested in...



Remicade Rheumatoid Arthritis X-Ray Data Sealed J&J Purchase Of Centocor

Interim data from Centocor's Remicade in rheumatoid arthritis, initially available to the company in mid-June, convinced Johnson & Johnson to purchase the biotechnology company.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

UsernamePublicRestriction

Register

PS063835

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel